Atherosclerosis Latest Advances

Shared decision-making in patients with abdominal aortic aneurysm and peripheral arterial disease: a qualitative study.

Journal: The Journal of cardiovascular surgery

Published: September 08, 2026

Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis.

Journal: Circulation

Published: September 08, 2026

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.

Journal: Expert opinion on pharmacotherapy

Published: September 08, 2026

Platelet proteome maps and their relevance to platelet activation and atherosclerosis.

Journal: Expert review of proteomics

Published: September 07, 2026

Loss of LRRK2 Protects Against Ox-LDL-Induced Endothelial Oxidative Damage Via NRF2.

Journal: Molecular and cellular biology

Published: September 07, 2026

High-dimensional adaptive immune cell patterns in coronary artery disease patients predict cardiovascular outcome.

Journal: European heart journal

Published: September 06, 2026

Atherosclerosis: cell biology and lipoproteins.

Journal: Current opinion in lipidology

Published: September 05, 2026

A Scandinavian Perspective of the Projected Lifetime Cost-Effectiveness of Rivaroxaban Plus Aspirin in the COMPASS Trial.

Journal: Scandinavian cardiovascular journal : SCJ

Published: September 05, 2026

Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Treatment Recommendations.

Journal: Cardiology in review

Published: September 04, 2026

Correction: A dual-targeting bio-liposomes nanodrug repair endothelial cell dysfunction and restore macrophage cholesterol flow homeostasis to treat early atherosclerosis.

Journal: Journal of nanobiotechnology

Published: September 03, 2026

Lipoprotein(a): Actionable today, treatable tomorrow?

Journal: Australian journal of general practice

Published: September 03, 2026

Corrigendum to: 'Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular risk' [JHEP Reports (2026) 19;8(9):101932].

Journal: JHEP reports : innovation in hepatology

Published: September 03, 2026

Atherosclerosis Latest Advances

Find the Latest Research About Atherosclerosis

Shared decision-making in patients with abdominal aortic aneurysm and peripheral arterial disease: a qualitative study.

Shared decision-making in patients with abdominal aortic aneurysm and peripheral arterial disease: a qualitative study.

Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis.

Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution in Tet2 Clonal Hematopoiesis.

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.

Platelet proteome maps and their relevance to platelet activation and atherosclerosis.

Platelet proteome maps and their relevance to platelet activation and atherosclerosis.

Loss of LRRK2 Protects Against Ox-LDL-Induced Endothelial Oxidative Damage Via NRF2.

Loss of LRRK2 Protects Against Ox-LDL-Induced Endothelial Oxidative Damage Via NRF2.

High-dimensional adaptive immune cell patterns in coronary artery disease patients predict cardiovascular outcome.

High-dimensional adaptive immune cell patterns in coronary artery disease patients predict cardiovascular outcome.

Atherosclerosis: cell biology and lipoproteins.

Atherosclerosis: cell biology and lipoproteins.

A Scandinavian Perspective of the Projected Lifetime Cost-Effectiveness of Rivaroxaban Plus Aspirin in the COMPASS Trial.

A Scandinavian Perspective of the Projected Lifetime Cost-Effectiveness of Rivaroxaban Plus Aspirin in the COMPASS Trial.

Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Treatment Recommendations.

Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Treatment Recommendations.

Correction: A dual-targeting bio-liposomes nanodrug repair endothelial cell dysfunction and restore macrophage cholesterol flow homeostasis to treat early atherosclerosis.

Correction: A dual-targeting bio-liposomes nanodrug repair endothelial cell dysfunction and restore macrophage cholesterol flow homeostasis to treat early atherosclerosis.

Lipoprotein(a): Actionable today, treatable tomorrow?

Lipoprotein(a): Actionable today, treatable tomorrow?

Corrigendum to: 'Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular risk' [JHEP Reports (2026) 19;8(9):101932].

Corrigendum to: 'Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular risk' [JHEP Reports (2026) 19;8(9):101932].